Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD5 CAR monocytes MT-101

A preparation of autologous monocytes genetically modified with mRNA technology to express a chimeric antigen receptor (CAR) specific for CD5, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD5 CAR monocytes MT-101 specifically recognize and bind to CD5-expressing tumor cells, and expose the immune system to the CD5 glycoprotein. This may elicit a cytotoxic T-lymphocyte (CTL) response against CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T cells and overexpressed on various B- and T-cell malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD5 CAR-M MT-101
CD5 ATAK CAR monocytes MT-101
mRNA-engineered CD5-CAR monocyte MT-101
mRNA-engineered CD5-CAR-M MT-101
Code name:MT 101
MT-101
MT101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search